Targeted therapy before surgery for EGFR-mutated lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests if taking a targeted therapy drug before surgery can help shrink tumors in people with a specific type of lung cancer called EGFR-mutated squamous cell carcinoma that can be removed with surgery. The goal is to see if this approach improves outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of lung cancer called squamous cell carcinoma that can be removed with surgery (stage II to IIIB).
- Your lung cancer has an EGFR mutation (a specific genetic change).
- A PET-CT scan shows the cancer has not spread to other parts of your body.
- You are in good overall health (ECOG score 0-1) and at least 18 years old.
- Your blood counts and liver/kidney function are within certain limits, and you are not pregnant or nursing.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether using a blood test to detect leftover tumor DNA after surgery can guide extra treatment for people with EGFR-mutant lung cancer. The goal is to see if starting or avoiding targeted therapy based on this test improves outcomes.
This trial studies osimertinib, a targeted medicine, after surgery to help stop lung cancer from growing or spreading. It’s for people with an early lung cancer that has EGFR mutations and leftover “ground-glass” lung spots in another area.
This trial tests two different treatment plans before lung cancer surgery. Both plans start with a targeted pill (limertinib), then one adds immunotherapy plus chemotherapy, and the other adds just chemotherapy. The goal is to see which combination helps shrink the tumor more before surgery.
This study tests whether giving osimertinib together with chemotherapy before surgery can shrink and control EGFR-mutant, stage III lung cancer so it can be fully removed. If it works, it may improve the chances that the cancer does not come back after surgery.
This trial tests whether adding targeted radiation or surgery to your regular osimertinib treatment can better control any remaining spots of lung cancer. It is for people with a specific EGFR mutation whose cancer has shrunk but left a few active sites.
This trial tests if taking osimertinib before surgery can help treat a type of non-small cell lung cancer that has specific EGFR mutations. It aims to understand how the cancer may become resistant to this targeted therapy.
Hear when a new Lung cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.